LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

LLY

1,021.53

+0.15%↑

JNJ

198.84

+0.64%↑

ABBV

234.93

+0.34%↑

UNH

310.95

-4.31%↓

AZN

89.04

-0.31%↓

Home・Aandelen Lijst・Altimmune Inc

Altimmune Inc

Gesloten

4.18 0.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.06

Max

4.21

Belangrijke statistieken
By Trading Economics
Inkomsten	3.1M -19M
Verkoop	5K
Winstmarge	-380,280
Werknemers	59
EBITDA	2.1M -21M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+305.73% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	95M 444M
Vorige openingsprijs	3.7
Vorige sluitingsprijs	4.18

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.365 / 6.0486 Steun & Weerstand

Altimmune Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 nov 2025, 18:59 UTC

Belangrijke Marktbewegers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov 2025, 23:40 UTC

Marktinformatie

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov 2025, 23:34 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov 2025, 22:58 UTC

Marktinformatie

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov 2025, 22:46 UTC

Marktinformatie

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov 2025, 22:02 UTC

Winsten

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov 2025, 21:40 UTC

Winsten

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov 2025, 21:39 UTC

Winsten

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov 2025, 21:38 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 21:38 UTC

Winsten

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q EPS BRL2.47 >XP

17 nov 2025, 21:10 UTC

Winsten

XP Inc. 3Q Rev BRL4.67B >XP

17 nov 2025, 20:20 UTC

Marktinformatie

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov 2025, 20:12 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 nov 2025, 20:09 UTC

Marktinformatie

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov 2025, 19:29 UTC

Marktinformatie

Gold Slide Continues to Start Week -- Market Talk

17 nov 2025, 19:16 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 18:20 UTC

Acquisities, Fusies, Overnames

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov 2025, 16:45 UTC

Acquisities, Fusies, Overnames

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov 2025, 16:16 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov 2025, 16:15 UTC

Winsten

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov 2025, 15:22 UTC

Acquisities, Fusies, Overnames

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov 2025, 15:19 UTC

Marktinformatie

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Vergelijking

Prijswijziging

Altimmune Inc Prognose

Koersdoel

By TipRanks

305.73% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 17 USD 305.73%

Hoogste 25 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Altimmune Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Altimmune Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.365 / 6.0486Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.